Updates in the Management of Chronic Kidney Disease and Type 2 Diabetes

Drs Rajiv Agarwal and Eugene Wright Jr. highlight risk factors associated with chronic kidney disease and react to concerns surrounding the assessment and treatment of patients.

Diagnostic criteria and special considerations of nephrologists when assessing patient kidney function and diagnosing chronic kidney disease.

Strategies to help clinicians talk with patients about chronic kidney disease staging and what to expect in terms of prognosis.

Financial and clinical concerns surrounding the burden of chronic kidney disease progression, as well as social determinants that factor into managing the condition in the community.

A panel of clinicians explain why action is needed to help prevent the risk of progression of chronic kidney disease.

Strategies that can help clinicians establish and work toward goals when treating patients with chronic kidney disease to help control disease and prevent progression.

Various types of health care professionals who may play a role in treating patients with chronic kidney disease, and recommendations to help overcome barriers that impact risk of disease progression and outcomes for patients.

Key takeaways from the National Kidney Foundation’s new HEDIS and MIPS quality measures for patients with chronic kidney disease and type 2 diabetes.

What better testing strategies and newer quality measures can do to improve patient referrals to nephrologists for earlier intervention of chronic kidney disease.

Considerations for establishing balance for the care of patients with chronic kidney disease among all types of care settings.

Therapies used to help treat patients who have chronic kidney disease and type 2 diabetes.

George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease.

What to know in terms of the mechanism of action of non-steroidal MRA finerenone compared with other therapies used to treat patients with chronic kidney disease and type 2 diabetes.

Where data demonstrated by the FIDELIO-DKD study of finerenone for patients with chronic kidney disease may apply in routine clinical practice.

A panel of clinicians react to limitations surrounding the use of SGLT2 inhibitors for patients with chronic kidney disease and type 2 diabetes.

An overview of therapies in the pipeline, including other nonsteroidal MRAs, that show potential in treating patients who have chronic kidney disease and type 2 diabetes.

Steps that need to be taken to address unmet needs and optimize outcomes for patients who have chronic kidney disease and type 2 diabetes.